Pharmaceutical Excipients Market

Pharmaceutical Excipients Market by Product (Organic (Oleochemicals, Carbohydrates) Inorganic (Calcium Carbonate), Functionality (Fillers, Binders, Lubricants, Diluents), Formulation (Oral, Parenteral), Application (Stablizers) & Region - Global Forecast to 2028

Report Code: PH 3047 Nov, 2023, by marketsandmarkets.com

The global pharmaceutical excipients market in terms of revenue was estimated to be worth $10.7 billion in 2023 and is poised to reach $14.9 billion by 2028, growing at a CAGR of 6.8% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. This is mainly due to various factors such as growing emphasis on patient-centric formulations, increasing demand for generic drugs and pharmaceutical products, increased R&D Investments for the development of novel excipients and collaborations and partnerships with pharmaceutical companies for customized excipient solutions. However, the growing high investments and development costs along with the growing regulatory stringency are predicted to cause market growth barriers.

Attractive Opportunities in the Pharmaceutical Excipients Market.

Pharmaceutical Excipients Market

To know about the assumptions considered for the study, Request for Free Sample Report

Pharmaceutical Excipients Market

Pharmaceutical Excipients Market Dynamics

Driver: Increasing demand for generic drugs and pharmaceutical products is propelling the demand for pharma excipients

The pharmaceutical excipients market is expected to benefit from the growing demand for generic drugs. Generic drugs are cheaper than branded drugs, and their entry into the market is expected to boost the volume of drugs sold. There is an increase in the number of generic drug approvals as due to patent cliff. Leading pharmaceutical companies with significant operations in the United States, such as Zydus Lifesciences, Torrent Pharma, Aurobindo Pharma, and Ajanta Pharma, are poised to reap substantial benefits from this development. Generic drug manufacturers are constantly looking for ways to reduce costs, and excipients can be a significant cost-saving measure. As a result, there is a growing demand for high-quality, affordable excipients which propels the pharmaceutical excipient market. This is considered a positive indicator of the growth of the pharmaceutical excipients market.

Restraint: High Development Costs associated with Novel excipients

The approval process for new excipients can be long, expensive and complex. It requires high capital investments and can further delay the time to market for new excipients, which can make it more difficult for pharmaceutical companies to justify the investment in developing new products. New excipients must be approved by regulatory agencies such as the FDA before they can be used in drug products. Additionally these excipients must be manufactured in large quantities to meet the needs of the pharmaceutical industry. This process can be lengthy and costly and thus is predicted to restrain the market.

Opportunity: Increasing growth of functional/Multifunctional Pharmaceutical Excipients

Co-processed multifunctional excipients are a class of pharmaceutical excipients that are created by combining two or more excipients together using a physical process, such as mixing, blending, or granulation. This process alters the physical properties of the individual excipients, resulting in a new excipient with enhanced functionality. These excipients offer several advantages over existing single function excipients such as reduced number of excipients in a formulation thus simplifying the manufacturing process, improved performance of the formulation due to superior flowability, compressibility, binding, and disintegrating properties compared to individual excipients and reduced variability in formulation properties by ensuring consistent batch-to-batch performance of pharmaceutical formulations therefore providing lucrative future market growth opportunities.

Challenge: Stringent Regulatory Requirements.

Stringent regulatory requirements are a significant challenge for the pharmaceutical excipients market. Regulatory bodies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have implemented strict guidelines for the manufacturing, testing, and use of excipients. These regulations are designed to ensure the safety and efficacy of pharmaceutical products. However, stringent regulatory requirements can also increase the complexity of developing and bringing new excipients to market. This can make it challenging for excipient manufacturers to innovate and keep up with the evolving demands of the pharmaceutical industry. For example, the U.S. FDA's rigorous New Drug Application (NDA) process and the European Medicines Agency's (EMA) regulatory requirements can significantly delay the introduction of innovative excipients.

Pharmaceutical Excipients Market Ecosystem Analysis

Pharmaceutical Excipients Market Ecosystem

The Oral Formulations segment commanded share of the pharmaceutical excipients industry in 2022.

On the basis of formulation, the global pharmaceutical excipients market is segmented into oral formulations (Tablets, Capsules, Liquid formulations and others), topical formulations, parenteral formulations and other formulations. The oral formulations segment dominated the pharmaceutical excipients market during the forecast period. Their wide usage and efficacy against many ailments. are some of the factors driving the market growth.

Lubricants and Glidants is likely to grow at significant CAGR in the pharmaceutical excipients industry during the forecast period

On the basis of functionality, the global pharmaceutical excipients market is segmented into fillers & diluents, suspending & viscosity agents, coating agents, binders, flavoring agents & sweeteners, disintegrants, colorants, lubricants & glidants, preservatives, emulsifying agents, and other functionalities. The fillers & diluents segment dominated the market share in 2022 and the lubricants and glidants segment is further expected to project the market growth at faster pace both due to their use in oral solid dosage forms which are the most popular dosage forms.

Asia Pacific predicted to exhibit highest CAGR in the pharmaceutical excipients industry during the forecast period of 2023-2028.

There are six main regional segmentations for the pharmaceutical excipients market—North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2022, Europe dominated the market share due to the presence of numerous large production capacity pharmaceutical giants which drive the high excipient consumption rates. The growing emphasis on superior generics, pharmaceutical products, and biosimilars has also increased the demand for novel excipients, which is predicted to drive market growth.

Pharmaceutical Excipients Market by Region

Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Key players in the Market include Ashland Inc. (US), Roquette Frères (France), Evonik Industries AG (Germany), International Flavors & Fragrances, Inc. (US), BASF SE (Germany), Kerry Group Plc (Ireland), Associated British Foods Plc (UK), Merck KGaA (Germany), Wacker Chemie AG (Germany) and ADM (US).

Scope of the Pharmaceutical Excipients Industry

Report Metric

Details

Market Revenue in 2023

$10.7 billion

Projected Revenue by 2028

$14.9 billion

Revenue Rate

Poised to Grow at a CAGR of 6.8%

Market Driver

Increasing demand for generic drugs and pharmaceutical products is propelling the demand for pharma excipients

Market Opportunity

Increasing growth of functional/Multifunctional Pharmaceutical Excipients

This report categorizes the pharmaceutical excipients market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Organic Chemicals
  • Oleochemicals
    • Fatty Alcohols
    • Mineral Stearates
    • Glycerin
    • Other Oleochemicals
  • Carbohydrates
    • Sugars
      • Actual Sugars
      • Sugar Alcohols
      • Artificial Sweetners
    • Cellulose
      • Microcrystalline cellulose
      • Cellulose ethers
      • Carboxymethyl cellulose (CMC) and croscarmellose sodium
      • Cellulose esters
    • Starch
      • Modified Starch
      • Dried Starch
      • Converted Starch
  • Petrochemicals
    • Glycols
    • Povidones
    • Mineral Hydrocarbons
    • Acrylic Polymers
    • Other Petrochemical Excipients
  • Proteins
  • Other Organic Chemicals
  • Inorganic Chemicals
  • Calcium Phosphate
  • Metal Oxides
  • Halites
  • Calcium Carbonate
  • Calcium Sulphate
  • Other Inorganic Chemicals
  • Other Chemicals

By Functionality

  • Fillers & Diluents
  • Suspending & Viscosity Agents
  • Coating Agents
  • Binders
  • Flavoring Agents & Sweeteners
  • Disintegrants
  • Colorants
  • Lubricants & Glidants
  • Preservatives
  • Emulsifying Agents
  • Other Functionalities

By Formulation

  • Oral Formulations
  • Tablets
  • Capsules
    • Hard-gelatin Capsules
    • Soft-gelatin Capsules
  • Liquid Formulations
  • Other Oral Formulations
  • Topical Formulations
  • Parenteral Formulations
  • Other Formulations

By Functionality Application

  • Taste Masking
  • Stablizers
  • Modified-Release
  • Solubility & Bioavailablity Enhancement
  • Others

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East
  • Africa

Recent Developments of Pharmaceutical Excipients Industry

  • In June 2023, Ashland introduced Polyplasdone Plus, a co-processed multifunctional direct compression superdisintegrant comprising a glidant and lubricant.
  • In October 2023, Lubrizol Life Science Health was awarded the Finished Formulation Award for Apisolex Polymer solubilizing excipient at CPhI Barcelona.
  • In July 2022, DFE Pharma announced the broadening of its Dry Powder Inhalation (DPI) portfolio by launching Lactohale 400.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION 
    1.1 OBJECTIVES OF THE STUDY 
    1.2 MARKET DEFINITION 
           1.2.1  INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1  MARKETS COVERED
           1.3.2  YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY 
    2.1 RESEARCH DATA 
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 INSIGHTS FROM PRIMARY
           2.2.2 SEGMENT ASSESMENT METHOLOGY
    2.3 GROWTH FORECAST 
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY 
 
4 PREMIUM INSIGHTS 
 
5 MARKET OVERVIEW 
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
           5.2.2 RESTRAINTS
           5.2.3 OPPORTUNITIES
           5.2.4 CHALLENGES
    5.3 TRENDS/DISTRUPTIONS IMPACTING CUSTOMERS BUSINESS 
    5.4 PRICING ANALYSIS 
           5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
           5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
    5.5 SUPPLY/VALUE CHAIN ANALYSIS 
    5.6 ECOSYSTEM ANALYSIS 
    5.7 TECHNOLOGY ANALYSIS 
    5.8 PATENT ANALYSIS 
    5.9 KEY CONFERENCES & EVENTS 2023-2024 
    5.10 TRADE DATA 
    5.11 TARIFF AND REGULATORY LANDSCAPE 
           5.11.1 REGULATORY BODIES, GOVERNMENT AGENICES AND OTHER ORGANIZATIONS
    5.12 PORTER’S FIVE FORCES’ ANALYSIS 
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTE
           5.12.3 BARGAINING POWER OF SUPPLIERS
                    5.12.4  BARGAINING POWER OF BUYERS
           5.12.5 INTENSITY OF COMPETITION RIVALRY
    5.13 KEY STAKEHOLDER AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
           5.13.2 BUYING CRITERIA
 
6 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT 
    6.1 INTRODUCTION 
    6.2 ORGANIC CHEMICALS 
           6.2.1 OLEOCHEMICALS
                    6.2.1.1 FATTY ALCOHOLS
                    6.2.1.2 MINERAL STEARATES
                    6.2.1.3 GLYCERIN
                    6.2.1.4 OTHER OLEOCHEMICALS
           6.2.2 CARBOHYDRATES
                    6.2.2.1 SUGARS
                               6.2.2.1.1. ACTUAL SUGARS
                               6.2.2.1.2. SUGAR ALCOHOLS
                               6.2.2.1.3. ARTIFICIAL SWEETENERS
                    6.2.2.2 CELLULOSE
                               6.2.2.2.1. MICROCRYSTALLINE CELLULOSE
                               6.2.2.2.2. CELLULOSE ETHERS
                               6.2.2.2.3. CMC & CROSCARMELLOSE SODIUM
                               6.2.2.2.4. CELLULOSE ESTERS
                    6.2.2.3 STARCH
                               6.2.2.3.1. MODIFIED STARCH
                               6.2.2.3.2. DRIED STARCH
                               6.2.2.3.3. CONVERTED STARCH
           6.2.3 PETROCHEMICALS
                    6.2.3.1 GLYCOLS
                    6.2.3.2 POVIDONES
                    6.2.3.3 MINERAL HYDROCARBONS
                    6.2.3.4 ACRYLIC POLYMERS
                    6.2.3.5 OTHER PETROCHEMICAL EXCIPIENTS
           6.2.4 PROTEINS
           6.2.5 OTHER ORGANIC CHEMICALS
    6.3 INORGANIC CHEMICALS 
           6.3.1 CALCIUM PHOSPHATE
           6.3.2  METAL OXIDES
           6.3.3 HALITES
           6.3.4 CALCIUM CARBONATE
           6.3.5 CALCIUM SULFATE
           6.3.6 OTHER INORGANIC CHEMICALS
    6.4 OTHER CHEMICALS 
Note: Other oleochemicals include natural waxes, specialty esters, phospholipids, ethoxylates, vegetable oils, hard fats, and mono and triglycerides among others. 
Note: Other petrochemicals include antioxidants, antimicrobials, dyes, and synthetic compounds such as disodium ethylenediamine tetra-acetate (EDTA), synthetic flavors, silicones, and other vinyl-based polymers. This segment also includes other synthetic materials, such as glycolic acid, hexylene glycol, and triethanolamine among others. 
Note: Other organic chemicals segment covers ethyl alcohol, isopropyl alcohol, lactic acid, citric acid, and shellac among others 
Note: The other inorganic chemicals segment includes clay, mineral alkalis, mineral acids, mineral buffering salts, and talc among others. 
Note: Other Chemicals includes pharmaceutical-grade water and mucilage among others 
Note: Tentative segmentation. This can be revised during the course of study. 
 
7 PHARMACEUTICAL EXCIPIENTS, BY FUNCTIONALITY 
    7.1 INTRODUCTION 
    7.2 FILLERS & DILUENTS 
    7.3 SUSPENDING & VISCOSITY AGENTS 
    7.4 COATING AGENTS 
    7.5 BINDERS 
    7.6 FLAVORING AGENTS & SWEETENERS 
    7.7 DISINTEGRANTS 
    7.8 COLORANTS 
    7.9 LUBRICANTS & GLIDANTS 
    7.10 PRESERVATIVES 
    7.11 EMULSIFYING AGENTS 
    7.12 OTHER FUNCTIONALITIES 
Note: Other functionalities include chelating agents, solvents, sorbents, plasticizers, humectants, adsorbents, buffers, wetting agents, anti-foaming agents, anti-adherents, emollients, and acidifying & alkalizing agents among others. 
Note: Tentative segmentation. This can be revised during the course of study. 
 
8 PHARMACEUTICAL EXCIPIENTS, BY FORMULATION (FORMS) 
    8.1 INTRODUCTION 
    8.2 ORAL FORMULATIONS 
           8.2.1 TABLETS
           8.2.2 CAPSULES
                    8.2.2.1 HARD-GELATIN CAPSULES
                    8.2.2.2 SOFT-GELATIN CAPSULES
           8.2.3 LIQUID FORMULATIONS
           8.2.4 OTHER ORAL FORMULATIONS
    8.3 TOPICAL FORMULATIONS 
    8.4 PARENTERAL FORMULATIONS 
    8.5 OTHER FORMULATIONS 
Note: Other oral formulations mainly include sublingual modes of delivery and semi-solid & solid dosage forms among others 
Note: Other formulations mainly include advanced drug formulations, such as those administered via inhalation, ocular, transdermal, liquid, semi-solid & solid dosage and amomg others 
Note: Tentative segmentation. This can be revised during the course of study. 
 
9 PHARMACEUTICAL EXCIPIENTS, BY FUNCTIONALITY APPLICATION 
    9.1 INTRODUCTION 
    9.2 TASTE MASKING 
    9.3 STABLIZERS 
    9.4 MODIFIED-RELEASE 
    9.5 SOLUBILITY & BIOAVAILABLITY ENHANCEMENT 
    9.6 OTHERS (IF ANY) 
Note: Modified Release is inclusive of delayed-release, extended-release, and targeted-release among others 
Note: Others segment includes manufacturing aids and among others.  
Note: Tentative segmentation. This can be revised during the course of study. 
 
10 PHARMACEUTICAL EXCIPIENTS, BY REGION 
     10.1 INTRODUCTION 
     10.2 NORTH AMERICA 
             10.2.1 US
             10.2.2 CANADA
             10.2.3 RECESSION IMPACT
     10.3 EUROPE 
             10.3.1 GERMANY
             10.3.2 FRANCE
             10.3.3 UK
             10.3.4 ITALY
             10.3.5 SPAIN
             10.3.6 REST OF EUROPE
             10.3.7 RECESSION IMPACT
     10.4 ASIA PACIFIC 
             10.4.1 JAPAN
             10.4.2 CHINA
             10.4.3 INDIA
             10.4.4 SOUTH KOREA
             10.4.5 REST OF ASIA PACIFIC 
             10.4.6 RECESSION IMPACT
     10.5 LATIN AMERICA 
             10.5.1 BRAZIL
             10.5.2 REST OF LATIN AMERICA
             10.5.3 RECESSION IMPACT
     10.6 MIDDLE EAST 
             10.6.1 RECESSION IMPACT
     10.7 AFRICA 
             10.7.1 RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE 
     11.1 INTRODUCTION  
     11.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN 
     11.3 REVENUE ANALYSIS 
     11.4 MARKET SHARE ANALYSIS 
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
             11.5.5 COMPANY FOOTPRINT
     11.6 START-UP/SME EVALUATION MATRIX 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
             11.6.5 COMPETITIVE BENCHMARKING
     11.7 COMPETITIVE SCENARIO AND TRENDS 
 
12 COMPANY PROFILES 
(Business Overview, Products Offered, Recent Developments, MnM View)*
     12.1 KEY COMPANIES 
             12.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
             12.1.2 ASHLAND INC.
             12.1.3 EVONIK INDUSTRIES AG
             12.1.4 BASF SE
             12.1.5 KERRY GROUP PLC
             12.1.6 ROQUETTE FRÈRES
             12.1.7 MERCK KGAA
             12.1.8 SPI PHARMA (ASSOCIATED BRITISH FOODS PLC)
             12.1.9 ADM
             12.1.10 WACKER CHEMIE AG
             12.1.11 AIR LIQUIDE
             12.1.12 DOW
             12.1.13 LUBRIZOL CORPORATION ( BERKSHIRE HATHAWAY INC.)
             12.1.14 COLORCON
             12.1.15 DFE PHARMA
     12.2 OTHER PLAYERS 
             12.2.1 INNOPHOS
             12.2.2 JRS PHARMA (J. RETTENMAIER & SÖHNE GMBH + CO KG)
             12.2.3 ACTYLIS
             12.2.4 MEGGLE GMBH & CO. KG
             12.2.5 COREL PHARMA CHEM.
             12.2.6 BIOGRUND GMBH
             12.2.7 NITIKA PHARMACEUTICAL SPECIALITIES PVT. LTD.
             12.2.8 BENEO
             12.2.9 FUJI CHEMICAL INDUSTRIES CO., LTD.
             12.2.10 R.T. VANDERBILT HOLDING COMPANY, INC.
 
13 APPENDIX 
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 AVAILABLE CUSTOMIZATIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the pharmaceutical excipients market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the pharmaceutical excipients market. The secondary sources used for this study include the European Federation of Pharmaceutical Industries and Associations (EFPIA), Pharmaceutical Research and Manufacturers of America (PhRMA), Parenteral Drug Association (PDA), International Pharmaceutical Excipients Council (IPEC), International Journal of Production Research (IJPR), Generics and Biosimilars Initiative (GaBI), PharmaTimes, World Journal of Pharmaceutical Sciences, International Federation of Pharmaceutical Manufacturers & Association (IFPMA), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global pharmaceutical excipients market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Pharmaceutical Excipients Market Size, and Share

Note: Tiers are defined based on a company’s total revenue. As of 2022, Tier 1 = >USD 1 Bn, Tier 2 = USD 500 Mn to USD 1 Bn, and Tier 3 <USD 500 Mn.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the pharmaceutical excipients market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the pharmaceutical excipients business of players operating in the market have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Market Size Estimation Methodology-Bottom-up approach

Pharmaceutical Excipients Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach-

Pharmaceutical Excipients Market Size, and Share

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Pharmaceutical excipients are inactive substances added to medications alongside the active pharmaceutical ingredient (API). They serve various purposes, such as improving the drug's stability, bioavailability, delivery, and overall effectiveness. These components, including preservatives, binders, fillers, disintegrants, lubricants, and flavoring agents, contribute to the final drug product's quality and efficacy.

Key Stakeholders

  • Manufacturers, importers & exporters, traders, distributors, and suppliers of pharmaceutical excipients
  • Pharmaceutical and biopharmaceutical companies
  • Distributors and suppliers of pharmaceutical excipients
  • Contract manufacturing organizations (CMOs)
  • Suppliers and distributors of pharmaceutical products
  • Research and development (R&D) companies
  • Pharmaceutical/medical associations
  • Regulatory bodies & government agencies
  • Research institutes and government organizations
  • Venture capitalists and investors
  • Business research and consulting service providers
  • Market research and consulting firms

The main objectives of this study are as follows:

  • To define, describe, and forecast the pharmaceutical excipients market based on product, functionality, formulation, functionality applicatons and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall antibody drug conjugate market.
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of the market segments with respect to six regions, namely: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), the Middle East  and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, expansions, and strategic alliances
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country-wise Information:

  • Analysis for additional countries (up to five)

Company Information:

  • Detailed analysis and profiling of additional market players (up to five)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 3047
Published ON
Nov, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Excipients Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback